Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Topical Antibiotics and Intravitreous Injections

This study has been completed.
Information provided by (Responsible Party):
Christopher Ta, Stanford University Identifier:
First received: October 2, 2006
Last updated: May 13, 2014
Last verified: May 2014
Evaluation of efficacy of topical preoperative antibiotics in patients undergoing intravitreous injections.

Condition Intervention Phase
Drug: gatifloxacin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Investigator)

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Conjunctival Bacterial Flora [ Time Frame: 3 days ] [ Designated as safety issue: No ]
    number of bacteria on the conjunctiva

  • Positive Culture [ Time Frame: 2 ] [ Designated as safety issue: No ]

Enrollment: 129
Study Start Date: July 2008
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: topical antibiotic
topical gatifloxacin 4 times per day
Drug: gatifloxacin


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • intravitreous injection

Exclusion Criteria:

  • antibiotic use
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00410891

United States, California
Stanford, California, United States, 94304
Sponsors and Collaborators
Stanford University
Principal Investigator: Christopher Ta, MD Stanford University
  More Information

Responsible Party: Christopher Ta, Principle Investigator, Stanford University Identifier: NCT00410891     History of Changes
Other Study ID Numbers: 96803 (eProtocol 4384 
Study First Received: October 2, 2006
Results First Received: May 13, 2014
Last Updated: May 13, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents processed this record on January 17, 2017